McNaughton Wealth Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

McNaughton Wealth Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 22.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,219 shares of the company’s stock after buying an additional 967 shares during the period. McNaughton Wealth Management LLC’s holdings in Johnson & Johnson were worth $818,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. GSG Advisors LLC increased its stake in Johnson & Johnson by 44.0% in the fourth quarter. GSG Advisors LLC now owns 5,521 shares of the company’s stock valued at $889,000 after purchasing an additional 1,686 shares during the last quarter. Rise Advisors LLC increased its stake in Johnson & Johnson by 32.3% in the fourth quarter. Rise Advisors LLC now owns 1,807 shares of the company’s stock valued at $283,000 after purchasing an additional 441 shares during the last quarter. Triangle Securities Wealth Management increased its stake in Johnson & Johnson by 0.4% in the fourth quarter. Triangle Securities Wealth Management now owns 19,399 shares of the company’s stock valued at $3,041,000 after purchasing an additional 84 shares during the last quarter. Falcon Wealth Planning increased its stake in Johnson & Johnson by 73.2% in the fourth quarter. Falcon Wealth Planning now owns 3,101 shares of the company’s stock valued at $486,000 after purchasing an additional 1,311 shares during the last quarter. Finally, Aurora Investment Managers LLC. increased its stake in Johnson & Johnson by 16.0% in the fourth quarter. Aurora Investment Managers LLC. now owns 3,620 shares of the company’s stock valued at $567,000 after purchasing an additional 500 shares during the last quarter. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the stock from $167.00 to $180.00 in a research report on Friday, December 1st. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Get Our Latest Research Report on JNJ

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $0.52 during midday trading on Tuesday, hitting $156.24. 1,052,270 shares of the stock were exchanged, compared to its average volume of 7,067,755. The stock has a market cap of $376.50 billion, a P/E ratio of 11.35, a PEG ratio of 2.66 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a 50 day moving average price of $159.48 and a 200-day moving average price of $156.87.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the previous year, the company posted $2.35 EPS. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.